A pproximately 130,000 cases of colorectal cancer are diagnosed in North America per year, resulting in 56,300 deaths. 1 5-FU/leucovorin has been the mainstay for first-line therapy of metastatic colorectal cancer over the last three decades. In recent years, Irinotecan, Xeloda, Oxaliplatin, Erbitux and Avastin have demonstrated activity in phase II and phase III studies and been approved for use in patients with metastatic colorectal cancer. [2] [3] [4] [5] [6] [7] [8] [9] With these new medications, the median time to progression among patients with metastatic colorectal cancer receiving first-line chemotherapy therapy is 8-9 months and the median survival is approximately 15-20.5 months. 3, 10, 11 Despite these recent improvements in the median survival of patients with metastatic colorectal cancer receiving first-line therapy, few patients are cured.
Most patients develop progressive disease and require second-line chemotherapy.
The response rates to standard second-line chemotherapeutic regimes including continuous infusion 5-FU, Irinotecan or Oxaliplatin are poor. The median time to progression for patients receiving second-line therapy is approximately 3 months and the median survival of these patients is 6-8 months. [12] [13] [14] [15] A randomized phase III trial compared continuous infusion 5-FU to Irinotecan among patients who had failed prior treatment with a 5-FU regimen. 10 Only one partial response (PR) (0.7%) was observed among 134 patients treated with continuous infusion 5-FU and 6 (4.5%) PRs were observed in the irinotecan arm. The median progression-free survival was 2.9 months for the patients receiving 5-FU and 4.3 months for the group receiving Irinotecan. A randomized phase III trial compared continuous infusion 5-FU, oxaliplatin and the combination of oxaliplatin with continuous infusion 5-FU (FOLFOX 4) among patients who had previously failed bolus 5-FU. 3 The median time to progression for patients receiving infusional 5-FU was 2.7 months and no objective responses were observed. Oxaliplatin, given as a single agent, was no better than infusional 5-FU, with an identical median time to progression of 2.7 months and no objective responses. The median time to progression of the patients receiving the combination of 5-FU/leucovorin and oxaliplatin was only 4.6 months and no objective responses were observed. These randomized studies confirm that the currently used chemotherapeutic agents including 5-FU, Irinotecan or Oxaliplatin, used as a single agent or in combination, have minimal activity among patients who have failed prior regiments with 5-FU. Since cytotoxic agents have little impact on the overall survival of patients with metastatic colorectal cancer who have failed first-line therapy, new approaches are needed to treat these patients.
One approach used for the minority of patients with limited metastatic involvement is surgical resection. Liver metastases can be resected with curative intent; however, the probability of achieving a cure is dependent on the number of tumor nodules and the disease-free interval. 16, 17 Curative surgical resection is unlikely among patients with multiple (44) tumor nodules and less than 5-10% of patients who present with metastatic colorectal cancer are candidates for curative surgery. Currently, the 5-year survival after curative liver resection for colorectal metastases is 25-35%, depending on various risk factors. [17] [18] [19] Systemic and intrahepatic administration of chemotherapy has been used to reduce the recurrence rates for following surgical resection, but the overall improvement in median survival with these approaches has been modest. [19] [20] [21] We conducted phase I/II studies of Onyx-015, an oncolytic adenovirus attenuated due to deletion of the viral E1b 55k gene. 22, 23 The E1b 55K protein is needed for effective replication of the virus in normal cells, but is not essential for viral replication in many tumor cell lines. [24] [25] [26] [27] Onyx-015 was administered by hepatic artery infusion to patients with metastatic colorectal cancer. The patients were given infusions of Onyx-015 as a single agent on days 1 and 8, followed by infusions of Onyx-015 in combination with 5-FU/leucovorin (Mayo regimen) given every 4-5 weeks starting on day 22. CT scans were performed at base line and after the second, third and fourth viral infusions, and with every other treatment thereafter. Patients without evidence of disease progression were permitted to have upto eight treatments with Onyx-015 combined with 5-FU/leucovorin. The primary end point of the study was the safety of Onyx-015 when given alone and in combination with 5-FU/leucovorin. No dose-limiting toxicities were observed during the study and the maximum feasible dose (2 Â 10 12 particles), as determined by manufacturing capabilities, was reached. The median survival was 12 months among a population of patients with extensive prior therapy. 22, 23 While the median survival for the patients treated on the study was encouraging, evaluation of the potential activity of Onyx-015 was complicated by the inclusion of 5-FU/leucovorin starting with the third infusion of Onyx-015. Since the response rate to 5-FU-based regimens is less than 1% among patients who have progressed on prior therapy with a 5-FU regimen, and since there are few effective options for patients that have failed first-line therapy, responses among these patients would be notable. This report focuses on the patients treated in the phase II trial with Onyx-015 who had failed prior therapy with 5-FU/ leucovorin, and thus would not be expected to respond to a re-administration of those agents.
Methods

Objectives
The objective of this analysis is to determine the antitumoral efficacy of Onyx-015 infusions in combination with 5-FU and leucovorin among patients with metastatic colorectal tumors within the liver, specifically among patients with colorectal tumors who have failed previous treatment with 5-FU and leucovorin.
Eligibility criteria
The eligibility criteria, vector and study design have been described previously. 22 Briefly, the inclusion criteria included the following: histologically-or cytologicallyconfirmed colorectal cancer; cancer that was not considered resectable for potential cure; confirmed hepatic artery perfusion of both liver lobes and 450% of all tumor mass(es); Karnofsky performance status of Z70%; life expectancy of Z3 months; Z18 years of age; consent form for study participation signed; must have been using a reliable method of contraception if sexually active or of reproductive potential; creatinine o2.0 mg/dl; AST and ALT o3.0-fold upper limit of the normal; total bilirubin o2.0 mg/dl; PT/INR o2.0 and PTT within normal limits; neutrophils 41500/ml, hemoglobin 49 gm/dl, platelets 4100,000/ml. Exclusion criteria were as follows: known chronic liver dysfunction prior to the development of metastatic cancer (e.g. cirrhosis, chronic hepatitis) which in the estimation of the Principal Investigator put the patient at high risk for liver complications; 450% liver replacement by tumor (estimated radiographically); history of esophageal variceal bleeding within the preceding 8 weeks; active infection, including documented human immunodeficiency virus; any viral syndrome diagnosed within the previous 2 weeks; chemotherapy within the previous 3 weeks (6 weeks for nitrosoureas or mitomycin-C); radiotherapy to the target tumor site within the last 4 weeks; concomitant hematological malignancy; chronic immunosuppressive medication; pregnant or lactating females; prior participation in any research protocol which involved administration of adenovirus vectors; treatment with any other investigational therapy within the last 4 weeks. As no single gold-standard test for p53 function within a tumor existed, p53 tumor status did not affect enrollment. However, the p53 gene status of the tumor was assessed by immunohistochemistry and DNA sequence analysis when sufficient amounts of tissue could be obtained.
Test article
ONYX-015 is a chimeric human group C adenovirus (Ad2 and Ad5) that does not express the 55 kDa product of the E1B gene. This vector was first constructed in the laboratory of Arnold Berk and was designed to determine the function of the E1b 55k viral protein. [28] [29] [30] [31] [32] The virus contains a deletion between nucleotides 2496 and 3323 in the E1B region encoding the 55 kDa protein. In addition, a C to T transition at position 2022 in E1B generates a stop codon at the third codon position of the protein. These alterations eliminate expression of the E1B 55 kDa gene. Onyx-015 was grown and titered on the human embryonic kidney cell line HEK293 as described previously.
Treatment schedule
The treatment schedule is summarized in Figure 1 . The safety of single agent Onyx-015 administered via the hepatic artery was determined following single infusions on days 1 and 8 (cycles 1 and 2). Starting on day 22, treatment cycles were 4-5 weeks and consisted of Onyx-015 infusions followed by intravenous chemotherapy within 6 hours following virus infusion. CT scans were obtained at day 22 and then prior to each infusion of Onyx-015 given in combination with 5-FU/leucovorin (approximately monthly). Up to eight cycles could be administered at the prerogative of the investigators, based on toxicity and tumor response.
Radiographic response
Bidimensional tumor measurements using World Health Organization criteria were used: progressive disease Z25% increase in cross-sectional area, PR Z50% reduction in cross-sectional area, complete response 100% reduction in cross-sectional area and stable disease o25% increase and o50% decrease in tumor crosssectional area.
Treatment procedures
The virus was administered during angiographic catheterization, unless an indwelling hepatic arterial port was already in place. Procedures were performed in interventional radiology suites. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance through a percutaneous femoral arterial approach. Patients were sedated with short-acting opiates and benzodiazepines as necessary for the procedure, and provided analgesics and antiemetics as necessary afterwards. Patients underwent diagnostic hepatic arteriograms immediately prior to the initial virus solution infusion to define arterial anatomy and to confirm hepatic arterial supply to intrahepatic tumor(s). Images were obtained by digital subtraction angiography (DSA). The existence of anomalous arterial anatomy, which may occur in upto 40% of the normal patient population, was established and documented. If there was a single branched hepatic artery, the infusion was given into the proper hepatic artery (distal to the origin of the gastroduodenal artery from the common hepatic artery). In the event of multiple arterial supply, the proportion of the liver supplied by each artery was estimated from the pretreatment CT scan and the arteriogram. The total dose was divided and administered into each artery according to the proportion of the liver supplied by that artery in order to provide even and complete distribution throughout the entire liver.
Frozen vialed virus solution was thawed and diluted with normal saline to the appropriate titer for each patient's dose level. Vials of Onyx-015 were opened and diluted in biological safety level 2 cabinets. Virus was maintained at 2-81C during dilution and handling, except for warming to room temperature immediately prior to administration. The virus solution was then further diluted to a final volume of 10 ml. The total viral dose administered was specified for the cohort. Dilutions were performed immediately prior to injection using disposable polyethylene syringes. After optimal positioning of the catheter to ensure minimal reflux into arterial branches not supplying the liver, a single infusion of 10 ml of viral solution was administered over approximately 5 minutes, followed by a 10 ml D5W/Electrolyte 48 solution flush given at the same rate and site. After completion of the infusion, the femoral catheter was removed. Vital sign assessments were taken at baseline, at the conclusion of the infusion, and then every 30 minutes for a total of 2 hours. Patients were observed overnight in the hospital post-injection at the discretion of the Principal Investigator.
For cycles 3 and 4 (starting on days 22 and 50), chemotherapy was given intravenously for 5 consecutive days starting within 6 hours after the Onyx-015 infusion. Leucovorin 20 mg/m 2 intravenously was followed by 5-FU 425 mg/m 2 /day by intravenous bolus. Up to four additional cycles of combination Onyx-015 and chemotherapy were allowable if the treatment was well tolerated and tumor progression had not been documented.
Statistical analysis
Survival was determined by the method of Kaplan-Meier using Prism statistical analysis software. Log rank test was used to compare differences in survival. Tumor volumes were determined by cross-sectional areas and the mean and 95% confidence intervals were calculated using Prism statistical software. 
Results
Patients enrolled
A total of 28 patients were enrolled in the Phase II study. Four patients did not qualify for this analysis. One patient had pancreatic cancer, one patient had no prior therapy with 5-FU/leucovorin and two patients had incomplete records of their prior therapies. The patient with pancreatic cancer survived 141 days, the patient without prior therapy survived 373 days, and the two patients with incomplete records survived 366 and 223 days. The median survival of all four patients was 9 months and the median survival of the three patients with colorectal cancer was 10 months. In all, 24 patients were eligible for this analysis.
Analysis of prior treatment
The distribution of treatments of the remaining 24 patients is shown in 
Survival analysis
A Kaplan-Meier plot of the overall survival of the 24 patients included in this study is shown in Figure 2 . The median survival for the 24 patients who had failed prior therapy with 5-FU was 10.7 months, 46% were alive at 1 year and 17% were alive at 2 years.
Radiographic response
Bidimensional tumor measurements using World Health Organization criteria were made after the two infusions of Prior treatment of the patients included in this analysis is shown. All patients received 5-FU-based therapy as first-line metastatic treatment and progressed on therapy or progressed during adjuvant treatment. The number of patients treated and the distribution of treatments are shown. 
Onyx-015 given as a single agent (day 22) and immediately prior to each subsequent infusion. The response was determined approximately 3 weeks after the four planned treatments with Onyx-015, which was approximately 3 months after initiation of treatment. After the planned four cycles of treatment, 11 patients (46%) had stable disease and two patients achieved PRs (66% and 72% reductions in total bidimensional tumor area) with additional therapy. Eight patients were removed from the study prior to completion of the four planned infusions of Onyx-015 for presumed progressive disease due to tumor enlargement greater than 25%. Previously, we described acute enlargement of tumor masses following infusion of Onyx-015, with subsequent regression of these masses in a subset of patients. 33 The finding of acute enlargement of the tumor masses is unique and may apply specifically to biological agents that can cause an inflammatory response. We defined regression as a reduction in tumor cross-sectional area of 410% from the maximal tumor size. Details of the basis of this analysis have been published previously. 33 Briefly, the 10% cutoff was established by randomly measuring the tumor volumes of a subset of CT scans from these patients. The standard deviation in the intraobserver measurement of the tumor masses determined by random readings was 5%. 10% is two standard deviations from the intraobserver mean. Analysis of the radiographic responses of these patients by these criteria revealed that 11 of the 24 patients (46%) demonstrated either regression or acute enlargement of the tumor masses followed by regression of 10% or greater (Fig 3a) . Seven of the 11 had transient increases near or exceeding the 25% cutoff limit. Two of the patients had transient enlargements in excess of 25% for the definition of progressive disease. These patients remained on study because other clinical criteria, including improved hepatic transaminases and evidence of necrosis on CT, suggested clinical benefit. The mean and 95% confidence interval for the bidimensional tumor area for these patients is shown (Fig 3b) . The median survival of the 11 patients with stable disease after four infusions of Onyx-015 was 19 months (Fig 4) . In contrast, the median survival of patients not demonstrating this response was six months, which is consistent with the expected survival for patients with metastatic colorectal cancer who have failed one or more prior treatments with 5-FU-based regimens. Survival of the group of patients with stable disease is significantly longer than the survival of patients with progressive disease (Po0.001). Notably, the patients with the two largest acute changes in tumor volume (48 and 33% increases over baseline at 3 weeks) who were kept on the study survived 19 and 25 months, respectively, after receiving treatment with Onyx-015.
The CT scan results of a patient who had failed three prior 5-FU-containing regimens prior to entry into the study are shown in Figure 5 . The best response to therapy with 5-FU-based treatment prior to enrollment in the study with Onyx-015 was a 12% reduction in tumor volume and the longest duration without radiographic progression was 8 months, which occurred following the initial treatment with 5-FU/leucovorin. The patient had rapidly progressive disease on the first CT (8 weeks) after starting the third 5-FU-based regimen administered and was referred for treatment on the experimental trial with Onyx-015. The baseline and subsequent CT scans for this patient are shown (Fig 5) . At the time of enrollment, the patient's liver was massively enlarged and extensively replaced by multiple tumor masses involving every segment (Fig 5 baseline) . The CT scan obtained following the two single-agent infusions of Onyx-015 demonstrated a 33% enlargement of the tumor masses; however, also noted was increased hypoattenuation and marginalization of the masses suggestive of tumor necrosis (Fig 5; day 28) . Following the third infusion, involution of the tumor masses was evident (day 51), but the bidimensional area increased to 37%. Subsequent treatments were associated with further involution of the tumor masses and declining tumor volume, and at the time of the last CT scan the patient had a 28% decrease compared to baseline. The (Fig 5; day 399) . Approximately 1 month after completing treatment with Onyx-015 trial, the patient received treatment with Irinotecan; however, this medication was discontinued without completing one full cycle due to severe diarrhea and the patient remained off chemotherapy. Although a contribution from the partial cycle of irinotecan cannot be excluded, the response to six cycles of Irinotecan among patients who had failed first-line treatment with 5-FU/ leucovorin was 4.5%. 10 Therefore, a response due a partial cycle of Irinotecan in a patient who had failed three prior treatment regimes is exceedingly unlikely. The patient eventually developed progressive disease with a predominant mass located in the anterior left lobe of the liver 21 months after initiation of treatment with Onyx-015. The 21-month interval before disease progression after receiving Onyx-015 significantly exceeded the longest previous progression-free interval (8 months). The patient's best response after receiving Onyx-015 was 490%, while the best response from the initial three regimens was 12%. It is also notable that the patient did not develop extrahepatic disease for over 2 years following treatment with Onyx-015. The patient received treatment with Xeloda, Irinotecan and Thalidomide at the time of progression without benefit, and then underwent chemoembolization with cisplatinum and adriamycin without benefit. The patient expired 25 months after starting treatment with Onyx-015.
Effect of p53
Tumors were analyzed for mutations in p53 by DNA sequencing and by immunohistochemistry. Using needle biopsies at the source of tissue, we were able to obtain reliable immunohistochemistry results for most patients, but were able to obtain reliable sequence data in seven of 24 samples. In six of seven cases where data from both methods were available, there was concordance between sequencing and immunohistochemistry. Tumors were considered to be mutant if either test demonstrated an abnormality. The survival of the patients by p53 status is shown (Fig 6) . Among these refractory patients, the median survival of patients whose tumors were p53 mutant was 5.5 months. In contrast, the median survival for the patients with wild-type p53 tumors was 16 months; however, given the number of patients, the results between the two groups are not significantly different (P40.05).
Study entry bias
Patients entering clinical trials may have a favorable outcome because patients are healthy enough to enter a trial or because their cancers are less aggressive. As a result, patients entering clinical trials may have a generally more favorable prognosis. This selection bias can result in falsely optimistic results. To evaluate the possibility that the patients entered in this trial had indolent disease, we analyzed the time from initial Figure 5 In May 1998, this 38-year-old man underwent surgical resection of a poorly differentiated adenocarcinoma of the sigmoid colon that had metastasized to the liver. Serum CEA was 57 ng/ml (normal o10) at the time of resection. Continuous intravenous infusion of 5-FU was initiated at 1 month post resection. A CT scan obtained 3 months after starting standard chemotherapy demonstrated a 12% reduction in tumor volume. A follow-up scan at 6 months demonstrated progressive disease and treatment was changed to bolus 5-FU. After 8 months (14 months post resection), a CT scan again demonstrated progressive disease and another continuous infusion 5-FU regimen was started. However, the patient demonstrated worsening abdominal pain and progressive disease within 4 weeks of starting treatment and was referred for consideration of treatment with Onyx-015. The patient received the last dose of continuous infusion 5-FU 15 months post resection. This patient demonstrated progression on three separate 5-FU-based regimens over a 15-month period. The baseline and subsequent CT scans are shown by days after initiation of treatment on the study. The baseline CT scan demonstrates extensive disease in all lobes of the liver. The patient received treatment with Onyx-015 on days 1 and 8 and a CT scan was obtained on day 28 that demonstrates enlargement and hypoattenuation of the tumor masses. The patient continued with monthly treatment with Onyx-015 in combination with 5-FU/leucovorin and extensive necrosis of the tumor masses is observed at day 138 (5 months). The necrotic masses have resolved by day 399 (14 months) and small areas of fibrosis and calcification and necrosis were observed (arrows). A single area suspicious for residual malignancy was noted (arrowhead). At the time of recurrence, only a single dominant mass (arrowhead) is observed (day 626-22 months).
Effects of Onyx-015 in metastatic colorectal cancer patients TR Reid et al diagnosis of metastatic colorectal cancer to entry into the study. The average time from diagnosis of liver metastases to entry into the Onyx-015 study was 17.3 months (5197382 days). This period of time is consistent with the fact that most patients had been treated with and failed two to three chemotherapy regimens prior to entering this study. Only two patients entered the trial more than 3 years after the diagnosis of metastatic disease. These two patients would be most likely to have biologically indolent disease that could result in prolonged survival, thus biasing the results of this study. One patient survived 25 months while the other patient survived only 6 months, and thus these patients had no significant effect on the median survival of the group.
Discussion
We previously reported on the phase I/II studies of Onyx-015 administered by arterial infusion for patients with metastatic colorectal cancer. 22, 23 While these studies demonstrated that Onxy-015 had no dose-limiting toxicity, a critical evaluation of the potential therapeutic activity of Onyx-015 is necessary to determine if further clinical development is warranted. The inclusion 5-FU/ leucovorin starting with the third infusion provided safety data for the combination of Onyx-015 with 5-FU/ leucovorin, but raised the possibility that any clinical benefit was due to the chemotherapy. Results from two large randomized trials recently completed demonstrated that the response rate to second-line 5-FU-based regimens is less than 1%. 3, 10 Therefore, responses in excess of 1% and/or median survival in excess of 6-8 months would provide a rationale for further study of the activity of Onyx-015 among patients with metastatic colorectal cancer. This analysis is restricted to those patients with documented progression while on treatment with 5-FUbased regimens.
All the patients included in this analysis progressed on 5-FU/leucovorin as first-line metastatic therapy. In all, 79% of the patients progressed on two or more chemotherapeutic regimens before entering the trial and 58% of the patients progressed on an Irinotecan-based regimen. Despite the extensive prior chemotherapy exposure of this population of patients, the median survival of these patients in this analysis was 10.7 months, 46% were alive at 1 year and 13% of the patients were alive at 2 years. In addition, two patients (8%) achieved PRs by standard radiographic criteria. These results compare favorably to other studies where the median survival of patients failing first-line therapy with a 5-FUbased regimen was 6-8 months and PR rates were less than 1%.
The response rate reported in this trial, 2/24 (8%), using standard radiographic response criteria may have underestimated the clinical benefit for two reasons. First, acute enlargement of the tumor masses may have resulted in the premature removal of patients who were potential responders to treatment. Eight of 24 (33%) patients were removed from the study before completion of the planned four infusions of Onyx-015 due to presumed progression by radiographic criteria (Z25% increase in the crosssectional measurement of the tumor masses). However, we demonstrate that patients with acute enlargements of tumor masses near to or exceeding the 25% definition of progression had subsequent tumor regressions and prolonged survival. Two patients had tumor enlargements exceeding the 25% definition for progression (33 and 48%), but were kept on the study because of clinical and biochemical evidence of improvement. The median survivals of these two patients were 25 and 19 months, respectively. Therefore, the acute enlargement of the tumor masses seen 3 weeks after initiation of therapy may not represent progression and some patients removed from the study because of enlargement of tumor masses observed at the 3-week CT scan may have been responders to the therapy. These patients may have benefited from additional treatment. Second, extensive necrosis of tumor masses resulted in delayed radiographic responses by conventional size-based criteria. 33, 34 Thus, the patient shown in Figure 5 was not formally considered a responder in the study since a radiographic response (50% reduction in tumor mass) was not achieved until 4 months after completion of the study. However, the patient clearly benefited from the study since he had failed three prior regimens over a 14-month interval before and the best radiographic response was 12%. In contrast, after treatment with Onyx-015, the patient had had a 490% reduction in tumor mass and a 21-month interval before disease progression.
We have previously demonstrated that tumor masses can become transiently enlarged following infusion of Onyx-015 and that the pattern of transient enlargement correlates with prolonged survival 3327. We also demonstrated that the radiographic response may lag clinical responses such as improvements in plasma hepatic transaminase and CEA levels. This report demonstrates that treatment with oncolytic viruses resulted in prolonged stable disease in nearly half of the patients who have failed prior treatment with 5-FU-based regimens. Stable disease following treatment with Onyx-015 may represent a significant reduction in viable tumor since the Figure 6 Kaplan-Meier survival curve for all patients in this analysis stratified by p53 status.
Effects of Onyx-015 in metastatic colorectal cancer patients TR Reid et al CT images from patients with stable disease demonstrate extensive necrosis of the tumor masses. Therefore, it may be possible to identify the group of responding patients by assessing changes in the metabolic activity of these tumors. Positron emission tomography (PET) uses labeled glucose to monitor the degree of metabolic activity in tumors. This technique has proven to be very useful for identifying tumor masses and predicting response to chemotherapy. [35] [36] [37] [38] The use of functional imaging, such as PET scans, may provide a more accurate measure tumor viability and augment the value of CT scans in determining tumor response among patients receiving treatment with oncolytic viruses.
The deletion of the viral E1b 55K gene results in attenuation of viral replication in normal cells. The lack of significant toxicity in the clinical trial supports attenuated nature of this vector. In tumor cells, abnormalities in the p53 pathway result in permissive replication. Recent reports demonstrate that the replication of Onyx-015 can occur by mechanisms other than mutation of p53. For example, replication of Onyx-015 is comparable whether the p53 pathway is inactivated by mutation in the p53 gene, or loss of function of the upstream regulator p14ARF, 25, 27 at least in cell culture. In this study, patients with mutant p53 had a poorer median survival than patients with wild-type p53; however, given the number of patients included in the analysis, the difference is not statistically significant (P40.05). Analysis of potential mechanisms for tumor-selective replication and tumor response among patients should be addressed in larger clinical studies.
Previously, we reported that treatment with Onyx-015 induces high levels of neutralizing antibodies in all patients. 22 The development of high titers of neutralizing antibody to the adenovirus was expected to limit the number of effective treatment cycles. However, prolonged survival and the two PRs were observed among patients receiving multiple treatment with Onyx-015 (4-8 infusions). Therefore, it is possible that continued therapy is necessary to achieve clinical responses among these patients and that additional clinical benefit may be derived from more than eight treatments. Arterial infusions may facilitate the infection of tumor cells, even in the presence of high titers of neutralizing antibody, by limiting the volume of distribution of the virus prior to contact with tumor cells.
The results of this analysis, which was restricted to patients with progression on treatment with 5-FU-based therapy, suggest that Onyx-015 has intrinsic and/or synergistic antitumor activity. No dose-limiting toxicities were observed with nearly 200 arterial infusions of Onyx-015 either as a single agent or in combination with 5-FU. 22 The median survival of patients who had failed prior therapy with 5-FU/leucovorin was 10.7 months. This compares favorably with the expected median survival of 6-8 months observed in randomized trials of patients receiving second-line therapy with 5-FU/Irinotecan or 5-FU/Oxaliplatin-based regimens. Two of the 24 (8%) patients in this analysis had PR by standard radiographic criteria, exceeding the 1% response rate observed in the second-line therapy with 5-FU/Irinotecan or 5-FU/Oxaliplatin regimens. The true response rate may be higher than 8%, since responding patients may have been removed early due to presumed progression and because standard radiographic response criteria may not capture relevant clinical responses. The use of functional imaging, such as PET scans, may help distinguish progressive disease from clinical responses among patients treated with oncolytic vectors. This trial was phase II safety trial and was not designed to eliminate sample error as the source of observed survival results. Given the low response to 5-FU among patients who have failed prior 5-FU treatment, these findings warrant further clinical investigation.
